{"title":"De-escalation of perioperative systemic therapy for early breast cancer.","authors":"Makiko Ono, Yasuaki Sagara, Toshiyuki Ishiba, Yukinori Ozaki, Takehiko Sakai, Hideo Shigematsu, Akihiko Shimomura, Kazuki Sudo, Kaori Terata, Yoichi Naito, Kazuki Nozawa, Fumikata Hara, Tomomi Fujisawa, Tadahiko Shien","doi":"10.1093/jjco/hyag131","DOIUrl":"10.1093/jjco/hyag131","url":null,"abstract":"<p><p>Breast cancer is the most common malignancy among women worldwide, and the number of survivors continues to increase owing to earlier detection and advances in treatment. As long-term survivorship becomes increasingly important, minimizing treatment-related toxicity without compromising oncologic outcomes has become a major goal in the management of early breast cancer. Treatment de-escalation strategies have therefore attracted considerable attention. In HER2-positive disease, several approaches have been explored, including reduction of chemotherapy intensity, shortening the duration of anti-HER2 therapy, chemotherapy-free regimens in selected patients, and response-guided strategies based on pathologic complete response following neoadjuvant therapy. In hormone receptor-positive HER2-negative breast cancer, multigene expression assays have enabled more precise risk stratification and have allowed omission of adjuvant chemotherapy in patients with biologically low-risk tumors. In addition, the neoadjuvant setting provides an opportunity to evaluate treatment response using biomarkers such as Ki67, which may help identify patients who can safely avoid chemotherapy. Ongoing clinical trials are further evaluating response-guided treatment strategies, particularly in premenopausal patients. Furthermore, circulating tumor DNA has recently emerged as a promising biomarker for detecting minimal residual disease and monitoring treatment response. Integration of molecular biomarkers with response-adapted strategies may further refine risk stratification and support personalized treatment approaches. This review summarizes current evidence and ongoing studies on treatment de-escalation across breast cancer subtypes.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1293-1298"},"PeriodicalIF":2.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic impact of regional lymph node metastasis at castration-resistant prostate cancer diagnosis on survival after radium-223 treatment.","authors":"Saizo Fujimoto, Takuma Kato, Masatoshi Eto, Mototaka Sato, Takahito Negishi, Akinori Wada, Tadamasa Shibuya, Jun Akatsuka, Shuichi Morizane, Tatsuya Takayama, Akira Tsujimura, Hiroki Kitou, Hiromasa Tsukino, Yoshihiro Matsunaga, Kazutoshi Fujita","doi":"10.1093/jjco/hyag125","DOIUrl":"10.1093/jjco/hyag125","url":null,"abstract":"<p><strong>Background: </strong>Radium-223 (Ra-223) is used for patients with bone-metastatic castration-resistant prostate cancer (CRPC). However, the prognostic value of regional lymph node metastasis at CRPC diagnosis for survival after Ra-223 remains unclear. This study evaluated the association between regional lymph node metastasis at CRPC diagnosis and overall survival (OS) after Ra-223 initiation.</p><p><strong>Methods: </strong>This multicenter retrospective cohort study used the Following Ra-223 in Outcomes after New-generation Therapy with Investigation of Effects in Refractory prostate cancer study database. Patients with bone-metastatic CRPC who initiated Ra-223 between January 2020 and December 2023 were included. Patients were classified according to the presence or absence of regional lymph node metastasis at CRPC diagnosis. The primary endpoint was OS from Ra-223 initiation. Cox proportional hazards regression was used to evaluate the association between regional lymph node metastasis and OS.</p><p><strong>Results: </strong>Among 802 patients who initiated Ra-223, 718 were included: 505 without regional lymph node metastasis and 213 with regional lymph node metastasis at CRPC diagnosis. Median OS was 31 months (95% confidence interval [CI], 26-35) and 17 months (95% CI, 16-22), respectively (log-rank P < 0.001). In multivariable analysis, regional lymph node metastasis at CRPC diagnosis was associated with poorer OS (hazard ratio, 1.396; 95% CI, 1.092-1.785; P = 0.008).</p><p><strong>Conclusions: </strong>Regional lymph node metastasis at CRPC diagnosis was associated with poorer OS after Ra-223 initiation. This status may provide prognostic information when considering subsequent treatment sequencing in bone-metastatic CRPC.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1428-1436"},"PeriodicalIF":2.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13766686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148684591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes.","authors":"Katsuya Hirano, Akito Hata, Yuta Yamanaka, Toshiyuki Sumi, Motohiro Tamiya, Yuki Sato, Yuko Oya, Kosuke Hamai, Nobuyuki Katakami, Katsuhiko Iwasaki, Tatsuhiro Uenishi, Kinya Kokubo, Ataru Igarashi","doi":"10.1093/jjco/hyag128","DOIUrl":"10.1093/jjco/hyag128","url":null,"abstract":"<p><strong>Background: </strong>Platinum-etoposide combined with a PD-L1 inhibitor (atezolizumab or durvalumab) is the standard first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). Although phase 3 trials have demonstrated similar efficacy, no direct comparison exists, and differences in treatment cost and resource utilization may influence clinical decision-making.</p><p><strong>Methods: </strong>In this multicenter retrospective study, real-world data from eight Japanese institutions were analyzed. Patients with ES-SCLC treated with platinum-etoposide plus atezolizumab or durvalumab between August 2018 and December 2022 were included. Individual-level medical costs were calculated from health insurance claims linked to electronic medical records. After propensity score matching and exclusion of cisplatin-treated patients, 128 patients were analyzed. The primary outcome was mean monthly medical cost during immunotherapy. Secondary outcomes included overall survival (OS), immune-related adverse events (irAEs), and prognostic factors.</p><p><strong>Results: </strong>Among 128 patients (mean age, 74 years; 85% male), mean monthly medical cost was significantly lower with atezolizumab than durvalumab (¥1 003 922 [$7183] vs ¥1 596 511 [$11 422]; P < .001). Median OS was comparable (13.9 months [95% CI, 11.7-17.5] vs 14.8 months [95% CI, 10.5-not reached]; P = .92). Grade ≥2 irAEs (11% vs 31%; P = .009) and interstitial lung disease (3% vs 20%; P = .004) were less frequent with atezolizumab. Poor performance status was associated with worse OS, whereas treatment type was not.</p><p><strong>Conclusions: </strong>Atezolizumab was associated with lower medical costs and similar survival outcomes compared with durvalumab in ES-SCLC, suggesting its use as a clinically comparable option with lower associated costs in Japanese real-world practice.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1387-1394"},"PeriodicalIF":2.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148759479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Fertility-sparing surgery for early-stage epithelial ovarian cancer: evolving criteria for patient selection.","authors":"Ayumi Shikama, Toyomi Satoh","doi":"10.1093/jjco/hyag194","DOIUrl":"https://doi.org/10.1093/jjco/hyag194","url":null,"abstract":"<p><p>Fertility-sparing surgery (FSS) is an important treatment option for young women with early-stage epithelial ovarian cancer (EOC). Stage IA, grade 1-2, non-clear-cell carcinoma is the most established indication, but whether FSS can be safely extended beyond this population remains uncertain. In 2010, Satoh et al. proposed a patient-selection framework based on stage, histologic subtype, and tumor grade, identifying stage IA clear-cell carcinoma (CCC) and unilateral stage IC non-clear-cell grade 1-2 disease as candidates for expanded FSS beyond this reference group (termed \"favorable histology\" in the original terminology). This review reassesses that framework using evidence accumulated through 2026. Only FSS cases with classifiable stage, histologic subtype, and grade were included in the descriptive oncologic synthesis, with CCC evaluated as a separate histologic category. Available evidence continues to support FSS for stage IA non-clear-cell grade 1-2 disease and, in carefully selected patients, unilateral stage IC non-clear-cell grade 1-2 disease. Increasing evidence supports considering FSS in appropriately staged stage IA CCC, although counseling should address the potentially poor salvageability of extra-ovarian recurrence. Evidence remains insufficient for routine FSS in high-grade disease or stage IC CCC. Retrospective evidence is limited by selection bias, historical staging systems, heterogeneous pathology, treatment variability, and overlapping cohorts. Further, a recent nationwide Japanese survey demonstrated substantial institutional variation in FSS practice. Prospective validation is therefore required to establish reproducible criteria for expanded indications. JCOG1203 is expected to determine whether FSS can safely be extended to these groups without compromising survival or increasing lethal recurrence.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Separating advance care planning from end-of-life care in Japan: a reframing for an era of improving cancer survival.","authors":"Akihiko Ozaki, Kazunoshin Tachibana, Yoshitake Takebayashi, Akemi Hara, Sunil Shrestha, Hideki Sato, Yasuhiro Kotera, Michio Murakami","doi":"10.1093/jjco/hyag191","DOIUrl":"https://doi.org/10.1093/jjco/hyag191","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149386531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Azole-mediated CYP3A inhibition and persistent gastrointestinal GVHD increase tacrolimus oral bioavailability after allo-HSCT.","authors":"Ryosuke Matsukane, Makoto Takahira, Yasuo Mori, Takuji Yamauchi, Sai Yasukochi, Shoji Nakamura, Shigeru Ishida, Kimitaka Suetsugu, Takehiro Kawashiri, Koji Kato, Koichi Akashi, Yoshikane Kikushige, Mayako Uchida","doi":"10.1093/jjco/hyag193","DOIUrl":"https://doi.org/10.1093/jjco/hyag193","url":null,"abstract":"<p><strong>Background: </strong>Tacrolimus exposure is critical after allogeneic hematopoietic stem cell transplantation (allo-HSCT). During intravenous-to-oral (IV-to-PO) conversion, the intestinal first-pass effect may be influenced by azole-mediated drug interactions and post-transplant gastrointestinal disturbances. However, the effects of newer azoles and gastrointestinal conditions on tacrolimus oral bioavailability remain unclear.</p><p><strong>Methods: </strong>We analyzed 179 allo-HSCT recipients undergoing tacrolimus IV-to-PO conversion. The dose-normalized concentration ratio ([C/Dpo]/[C/Div]) was used as a bioavailability index reflecting changes associated with oral administration. Associations of antifungal therapy, diarrhea, and gastrointestinal graft-versus-host disease (GI-GVHD) with the tacrolimus bioavailability index were assessed.</p><p><strong>Results: </strong>Median tacrolimus bioavailability index values were 0.15 with non-azole agents, 0.20 with fluconazole or isavuconazole, and 0.32 and 0.34 with voriconazole and posaconazole, respectively. GI-GVHD had developed in 33 patients, and diarrhea was present in 59 patients at conversion. In multivariable analysis, moderate CYP3A inhibitors (fluconazole/isavuconazole) were associated with increased bioavailability index (β = 0.092, 95% CI 0.025-0.158, P = .007), with a greater effect of strong CYP3A inhibitors (voriconazole/posaconazole; β = 0.205, 95% CI 0.143-0.266, P < .001). Persistent GI-GVHD was associated with the largest increase (β = 0.235, 95% CI 0.150-0.320, P < .001), whereas diarrhea was not. Furthermore, persistent GI-GVHD was independently associated with tacrolimus overexposure after oral conversion (adjusted odds ratio 6.82, 95% CI 1.54-30.20).</p><p><strong>Conclusions: </strong>Tacrolimus bioavailability index during IV-to-PO conversion varies according to azole CYP3A inhibitory potency and persistent GI-GVHD, with the latter independently associated with post-conversion overexposure. Initial oral dosing should account for both factors and be subsequently optimized by therapeutic drug monitoring to minimize excessive tacrolimus exposure.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149386530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metastasis-directed radiotherapy for oligoprogressive castration-resistant prostate cancer: clinical outcomes and factors associated with durable disease control.","authors":"Yuichiro Nakamura, Shu Okamoto, Yujiro Hayashi, Kensuke Mitsunari, Norihiko Kawamura, Akira Nagahara, Yasutomo Nakai, Koji Konishi, Masahiro Morimoto, Naoyuki Kanayama, Ryoichi Imamura, Masashi Nakayama, Kazuo Nishimura","doi":"10.1093/jjco/hyag192","DOIUrl":"https://doi.org/10.1093/jjco/hyag192","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to evaluate clinical outcomes after metastasis-directed radiotherapy (MDRT) in patients with oligoprogressive castration-resistant prostate cancer (CRPC) and to identify factors associated with durable disease control.</p><p><strong>Methods: </strong>We retrospectively analyzed 43 patients with oligoprogressive CRPC who underwent MDRT between 2020 and 2024 at a single institution. The primary endpoint was progression-free survival (PFS), defined using composite criteria from the Prostate Cancer Working Group 3 and Response Evaluation Criteria in Solid Tumors. Secondary endpoints included prostate-specific antigen (PSA) response and secondary PFS (PFS2) in patients who underwent repeat MDRT. Clinical factors associated with PFS were assessed by Cox proportional hazards regression.</p><p><strong>Results: </strong>The median PFS after initial MDRT was 9.0 months (95% confidence interval [CI], 7.0-11.0). A PSA decline of ≥50% was achieved in 53% of patients, including a ≥ 90% decline in 21%. Thirteen patients (30%) underwent repeat MDRT for recurrent oligoprogression, with a median PFS2 of 14.0 months (95% CI, 10.0-25.0). In multivariable analysis, prior androgen receptor signaling inhibitor (ARSI) exposure for CRPC (hazard ratio [HR], 4.53; 95% CI, 1.75-11.73) and PSA doubling time ≤ 2.4 months (HR, 3.24; 95% CI, 1.29-8.15) were independently associated with shorter PFS. No grade ≥ 3 treatment-related adverse events were observed.</p><p><strong>Conclusions: </strong>MDRT was followed by clinically meaningful disease control in patients with oligoprogressive CRPC. Prior ARSI exposure for CRPC and a shorter PSA doubling time were associated with earlier progression. These findings are exploratory and warrant validation in prospective studies.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149333923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hasan Jamil, Aminu Kende Abubakar, Hirokazu Tanaka, Kota Katanoda
{"title":"Northward shift in cancer mortality inequality across Japanese prefectures, 1995-2023, a nationwide ecological study.","authors":"Hasan Jamil, Aminu Kende Abubakar, Hirokazu Tanaka, Kota Katanoda","doi":"10.1093/jjco/hyag190","DOIUrl":"https://doi.org/10.1093/jjco/hyag190","url":null,"abstract":"<p><strong>Background: </strong>Cancer has been the leading cause of death in Japan since the 1980s, with known variation across prefectures, but evidence on how this pattern has changed over time is limited.</p><p><strong>Methods: </strong>We analysed age-standardized cancer mortality across all 47 Japanese prefectures in 1995 and 2023 using vital statistics data. For each prefecture, excess mortality was calculated relative to a leave-one-out national reference and standardized to the 1995 national population. Excess mortality was decomposed by cancer site. We also compared prefectures' age-standardized mortality rates (ASMRs) between the two years.</p><p><strong>Results: </strong>All-cancer ASMR declined in every prefecture. In 2023, excess mortality ranged from 32·6 per 100 000 (95% CI 26·8 to 38·4) in Aomori to -22·4 (-26·1 to -18·6) in Nagano, a gap of 55·0 deaths per 100 000, with 30 prefectures differing significantly from the national reference. The geographic pattern shifted between 1995 and 2023. In 1995, excess mortality was concentrated in western Japan, particularly Osaka and Fukuoka, and was largely driven by liver cancer. By 2023, excess mortality had shifted to northern prefectures, led by Aomori and Hokkaido, and was distributed across multiple cancer types, including colorectal, lung, and stomach cancer. The overall gap narrowed from 69·6 to 55·0 per 100 000.</p><p><strong>Conclusions: </strong>Geographic inequality in cancer mortality persisted in Japan, but its pattern changed substantially. The findings suggest that national cancer control should monitor subnational inequality directly and support regionally targeted strategies.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149333924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}